Cargando…

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, C H, Tsai, C M, Wang, L S, Lee, Y C, Chang, C J, Lui, L T, Yen, S H, Hsu, C, Cheng, A L, Liu, M Y, Chiang, S C, Chen, Y M, Luh, K T, Huang, M H, Yang, P-C, Perng, R-P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375194/
https://www.ncbi.nlm.nih.gov/pubmed/11870504
http://dx.doi.org/10.1038/sj.bjc.6600044
_version_ 1782154599174504448
author Yang, C H
Tsai, C M
Wang, L S
Lee, Y C
Chang, C J
Lui, L T
Yen, S H
Hsu, C
Cheng, A L
Liu, M Y
Chiang, S C
Chen, Y M
Luh, K T
Huang, M H
Yang, P-C
Perng, R-P
author_facet Yang, C H
Tsai, C M
Wang, L S
Lee, Y C
Chang, C J
Lui, L T
Yen, S H
Hsu, C
Cheng, A L
Liu, M Y
Chiang, S C
Chen, Y M
Luh, K T
Huang, M H
Yang, P-C
Perng, R-P
author_sort Yang, C H
collection PubMed
description The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m(−2), days 1, 8, 15) and cisplatin (90 mg m(−2), day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients. British Journal of Cancer (2002) 86, 190–195. DOI: 10.1038/sj/bjc/6600044 www.bjcancer.com © 2002 The Cancer Research Campaign
format Text
id pubmed-2375194
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23751942009-09-10 Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer Yang, C H Tsai, C M Wang, L S Lee, Y C Chang, C J Lui, L T Yen, S H Hsu, C Cheng, A L Liu, M Y Chiang, S C Chen, Y M Luh, K T Huang, M H Yang, P-C Perng, R-P Br J Cancer Clinical The role of new cytotoxic agents like gemcitabine has not yet been proven in the neoadjuvant settings. We designed a phase II study to test the feasibility of using gemcitabine and cisplatin before local treatment for stage III non-small cell lung cancer patients. Patients received three cycles of induction chemotherapy of gemcitabine (1000 mg m(−2), days 1, 8, 15) and cisplatin (90 mg m(−2), day 15) every 4 weeks before evaluation for operability. Operable patients underwent radical resection. Inoperable patients and patients who had incomplete resection received concurrent chemoradiotherapy with daily low dose cisplatin. All patients who did not progress after local treatment received three more cycles of adjuvant chemotherapy of gemcitabine and cisplatin. Fifty-two patients received induction treatment. Two patients had complete response and 31 patients had partial response (response rate 63.5%) after induction chemotherapy. Thirty-six patients (69%) were operable. Eighteen patients (35%) had their tumours completely resected. Two patients had pathological complete response. Median overall survival was 19.1 months, projected 1-year survival was 66% and 2-year survival was 34%. Three cycles of gemcitabine and cisplatin is effective and can be used as induction treatment before surgery for locally advanced non-small cell lung cancer patients. British Journal of Cancer (2002) 86, 190–195. DOI: 10.1038/sj/bjc/6600044 www.bjcancer.com © 2002 The Cancer Research Campaign Nature Publishing Group 2002-01-21 /pmc/articles/PMC2375194/ /pubmed/11870504 http://dx.doi.org/10.1038/sj.bjc.6600044 Text en Copyright © 2002 The Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Yang, C H
Tsai, C M
Wang, L S
Lee, Y C
Chang, C J
Lui, L T
Yen, S H
Hsu, C
Cheng, A L
Liu, M Y
Chiang, S C
Chen, Y M
Luh, K T
Huang, M H
Yang, P-C
Perng, R-P
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
title Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
title_full Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
title_fullStr Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
title_full_unstemmed Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
title_short Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
title_sort gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375194/
https://www.ncbi.nlm.nih.gov/pubmed/11870504
http://dx.doi.org/10.1038/sj.bjc.6600044
work_keys_str_mv AT yangch gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT tsaicm gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT wangls gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT leeyc gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT changcj gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT luilt gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT yensh gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT hsuc gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT chengal gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT liumy gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT chiangsc gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT chenym gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT luhkt gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT huangmh gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT yangpc gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer
AT perngrp gemcitabineandcisplatininamultimodalitytreatmentforlocallyadvancednonsmallcelllungcancer